A randomized study investigating the effect of alirocumab on coronary atherosclerosis in patients with acute myocardial infarction was published on 2022-01-01. The study, known as PACMAN-AMI, evaluated alirocumab when added to high-intensity statin therapy.
Background
The study investigated alirocumab (Praluent) in the context of acute myocardial infarction. Specifically, it explored the impact of adding alirocumab to existing high-intensity statin therapy for patients experiencing acute myocardial infarction, focusing on its effects on coronary atherosclerosis.
Trial design
The PACMAN-AMI study was a randomized trial designed to assess the effects of alirocumab. It focused on patients who had experienced acute myocardial infarction and were receiving high-intensity statin therapy, examining the impact of alirocumab on coronary atherosclerosis.
What this means
The publication of the PACMAN-AMI study makes its findings on alirocumab available to the medical community. Clinicians and researchers can now review the detailed results regarding the effect of adding alirocumab to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction. This contributes to the understanding of lipid-lowering strategies in this high-risk population.
Source
The information regarding this study was published in JAMA and made available via PubMed on 2022-01-01. The article is titled "Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized" and can be accessed on pubmed.ncbi.nlm.nih.gov.